# Sorafenib and Bortezomib in Treating Patients With Advanced Cancer

> **NCT00303797** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 50 (actual)

## Conditions studied

- Refractory Chronic Lymphocytic Leukemia
- Refractory Multiple Myeloma
- Stage III Multiple Myeloma
- Stage IV Chronic Lymphocytic Leukemia
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** 17-N-allylamino-17-demethoxygeldanamycin/bortezomib
- **DRUG:** sorafenib tosylate

## Key facts

- **NCT ID:** NCT00303797
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2010-05
- **Final completion:** —
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2013-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00303797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00303797, "Sorafenib and Bortezomib in Treating Patients With Advanced Cancer". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00303797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*